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Idiopathic pulmonary fibrosis is a rare, life threatening disease characterized by an anarchic fibrogenesis, limited
survival and few therapeutic options. Its pathogenesis is complex and involves the interaction among various
pathways driven by proinflammatory/profibrogenetic mediators such as platelet -derived growth factor, vascular
endothelial growth factor or basic fibroblast growth factor. Given their prominent pathogenic roles in this disease
such growth factor might be suitable therapeutic targets.In fact, the existing preclinical and clinical data
demonstrated that their therapeutic inhibition results in a delayed progression of the pulmonary fibrosis and in the
improvement of the disease outcome. BIBF 1120 is a potent triple blocker of the receptors of these growth factors
which is currently evaluated as a potential therapy in the idiopathic pulmonary fibrosis. This review discusses the
existing data supporting its potential use in this disease.
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Idiopathic pulmonary fibrosis (IPF) is a rare life-threatening
disease of the lungs characterized by a rapidly progressive
fibrogenesis, limited survival and by limited therapeutic
resources. The poor disease outcome is due not only to the
fact that there are only few therapies available, but also to
the rather modest antifibrotic effects of treatments such as
corticosteroids, cyclophosphamide or azathioprine which
are conventionally used as the first line approach in such
patients [1]. More recently, pirfenidone, was approved as
the first antifibrotic therapy for IPF based on demonstrated
sustained clinical efficacy [2]. Other investigational drugs
are currently assessed in the same setting and these include
anticoagulant agents, anti growth factors agents or antioxi-
dant molecules. Growth factor antagonists in particular are
of promise due to their potent antifibrotic effects demon-
strated in other similar settings [3,4].
BIBF 1120 is a triple tyrosin kinase inhibitor and a po-
tent antagonist of growth factors such as platelet-derived
growth factor, vascular endothelial growth factor and
basic fibroblast growth factor, and it is currently evalu-
ated in clinical trials as a potential IPF therapy.Correspondence: sabinaantoniu@yahoo.com
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reproduction in any medium, provided the orThis paper summarizes the rationale of its use in this
disease based on existing evidence.Scientific rationale of tyrosin kinases inhibition in the IPF
Mediators such as platelet-derived growth factor (PDGF),
vascular-endothelial growth factor (VEGF) and basic
fibroblast growth factor (bFGF) are currently individually
or collectively investigated as potential therapeutic tar-
gets for diseases such as cancers, pulmonary hyperten-
sion or idiopathic pulmonary fibrosis. VEGF, PDGF or
FGF are now known mitogenic factors playing major
pathogenic roles in tumour angiogenesis, extracellular
matrix proliferation and fibrogenesis [5]. VEGF for ex-
ample was found to be over expressed by tumour cells in
response to tissue hypoxemia and was reported to in-
crease proliferation and migration of the endothelial cells
and to inhibit their apoptosis [6,7]. PDGF is another
growth factor which was found to be involved in the
pathogenesis of various proliferative disorders such as
tumours, or pulmonary fibrosis in which it was found to
stimulate proliferation of smooth muscle cells as well as
fibrogenesis [6,8]. In a mouse model of silica-exposure-
induced lung fibrosis, PDGF-BB was found to be over
expressed via a TGF-β-mediated autocrine pathway [8].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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smooth muscle cells, myofibroblasts, and fibroblasts and
its expression was found to be up regulated in IPF [7].
Given the potent mitogenic effects of these growth
factors, their inhibition is expected to reduce the angio-
genesis and the fibrosis and in fact such effects are
already used in cancer therapy and evaluated in various
forms of cancer as well as in other diseases such as
pulmonary fibrosis or IPF [9].
The inhibition of such factors can be achieved via
different approaches, the most used and evaluated cur-
rently being the related receptors inhibition. VEGFR,
PDGFR and bFGFR are tyrosine kinases which become
activated upon ligand binding and stimulate the down-
stream signaling pathways [5].
Imatinibmesylate, another tyrosin kinase inhibitors
which acts specifically on PDGF was initially evaluated
for its potential antifibrotic effects in preclinical and
clinical studies. In experimental studies imatinib was
found to inhibit fibroblast proliferation, and collagen
deposition in vitro and in vivo [10].
When evaluated in a clinical study in patients with
IPF, imatinib given once daily at a dosage of 600 mg/day,
for 96 weeks demonstrated no significant benefit over
placebo in slowing disease progression or lung function
impairment [11].
However, the multiple inhibition of such growth fac-
tors might be associated with a more potent antifibrotic
effect: in a preclinical study performed in the mice
model of bleomycin-induced pulmonary fibrosis, BIBF
1000 a triple kinase inhibitor for the PDGFR, VEGFR
and bFGFR was found to attenuate bleomycin-induced
lung fibrogenesis by reducing the expression of the pro-
fibrogenetic factors and by decreasing the collagen lung
content [12]. In a an ex vivo assay performed on human
bronchial fibroblasts BIBF 1000 inhibited TGF-β-induced
myofibroblast differentiation [12].
BIBF 1120 (nintedanib), an oxindole derivative is a
triple kinase inhibitor with potent suppressing effects
on VEGFR, PDGFR and bFGFR [9]. Nintedanib is cur-
rently in advanced clinical testing for various types of
advanced solid cancers as a potential antiangiogenic
therapy to be added to the cytotoxic agents to exert
synergistic antitumour effects. The antiangiogenic
effects of nintedanib were demonstrated in various pre-
clinical studies such including inhibition of proliferation
of HUVEC cell line or animal models of xenografttu-
mour, as well as in clinical trials in subjects with
advanced non-small cell lung cancer or gastrointestinal
tumours [9].
Clinical data with BIBF1120 in IPF
BIBF 1120 was assessed in many clinical studies per-
formed in a wide range of solid malignancies includingnon-small cell lung cancer (NSCLC) as an antiangiogenic
therapy and in few clinical studies as a potential antifibro-
tic therapy in IPF [9].
The TOMORROW (To Improve Pulmonary Fibrosis
with BIBF-1120) study was a 12 month, randomized,
placebo controlled, phase II study evaluating the efficacy
and safety of four nintedanib doses (50 mg once daily,
50 mg twice daily, 100 mg twice daily, 150 mg twice
daily) in patients with idiopathic pulmonary fibrosis [13].
Patients aged at least 40 years with a predefined IPF
diagnosis of less than 5 years prior to the study screen-
ing were included in the study. Eligible patients had a
FVC≥50% and a DLCOpred 30-79% and a PaO2
≥55mmHg. Concomitant oral therapy with prednisone
(or equivalents) of ≤15 mg if stable during the 8 weeks
previous to the study enrollment [13].
The primary efficacy endpoint was represented by the
FVC decline rate and the secondary endpoints included
changes from baseline in FVC, DLco, SpO2, TLC, exer-
cise capacity, SGRQ (St. George respiratory question-
naire) scores, the incidence of acute exacerbations,
overall mortality, and that due to respiratory causes.
The highest BIBF 1120 dose was associated with the
most significant therapeutic effect on the lung function
decline compared to placebo, the drug reducing the
annual rate of lung function decline by 68.4% com-
pared to placebo group.
The highest dose of BIBF 1120 therapy was also asso-
ciated with a lower percentage of patients exhibiting a
significant reduction of the FVC (of >10% or of >200ml)
compared to placebo (23.8% versus 44%, p=0.004). Un-
like placebo BIBF 1120 preserved the total lung capacity
(−0.24 liters vs. 0.12 liters, p<0.001).
Mean change from baseline in the SpO2 was −0.2%
with BIBF 1120 and −1.3% with placebo (p = 0.02). The
highest dose therapy was also associated with a lower
percentage of significant desaturation (>4% reduction
from baseline in resting SpO2) over the study period
3.6% respectively 11.0%, p = 0.03). BIBF 1120 didn’t
exert a significant therapeutic benefit on the DLCO and
in the exercise capacity as compared to placebo.
Health Related Quality-of-Life (HRQoL) evaluated
with SGRQ was found to be significantly improved
with the BIBF highest dose as compared to placebo
the difference being also clinically significant: mean
change −0.66 points with the active treatment com-
pared to 5.46 points with placebo p = 0.007. The do-
main analysis demonstrated that the significant
therapeutic effect on HRQoL was due to the signifi-
cant improvements in symptoms and activity domains
(−3.14 points with BIBF 1120 compared to 6.45 points
with placebo, p = 0.003 and 0.32 points with BIBF
1120 compared to 7.48 points, p = 0.004). A dose-
dependent trend toward a reduction of the score of
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the BIBF 1120. The proportion of patients with a clin-
ically significant improvement in the HRQoL scores
was higher in the treatment arms 100 mg and 150 mg
(32.6% and 29.1%, respectively) versus placebo group
(16.1%; p = 0.007 and p = 0.03, respectively). An in-
depth analysis of the HRQoL and dyspnea change over
baseline was also conducted. It was found a risk of dys-
pnea worsening versus baseline in a comparable number
(%) of patients irrespective of the treatment allocation:
31(40.3%) in placebo arm, 31(41.3%) with BIBF-1120
50 mg/day 31(38.3%) BIBF-1120 100 mg/day, 33(40.2%)
BIBF-1120 200 mg/day, 26(34.2%) BIBF-1120 300 mg/day.
For the HRQoL however, a dose dependent improvement
was demonstrated: 0.79 units with BIBF-1120 50 mg/day,
3.28 units with BIBF-1120 100 mg/day, 3.98 units with
BIBF-1120 200 mg/day, 6.12 units with BIBF-1120 300
mg/day (p=0.0071 for the highest dose versus placebo).
The overall HRQoL worsening in the placebo armwas also
clinically significant (MCID 4 units of score). The most
significant therapeutic benefit was detected in the SGRQ
symptoms score: 9.6 units improvement with BIBF 1120
compared to placebo (p=0.0028). The likelihood of a
clinically significant improvement was the highest with
BIBF 1120 200 mg/day, (odds ratio 2.7, p=0.0069).
Mean HRQoL change was found to correlate inversely
with mean FVC change (r =0.0304, p=0.0081) [14].
BIBF 1120 highest dose was associated with a signifi-
cant reduction of the incidence of acute exacerbations
compared to placebo (2.4 versus 15.7 per 100 patient-
years, p = 0.02), and a trend towards a dose-dependent
increase in the effect size with the 100 mg dose was
also noted. The 150 and the 100mg BIBF1120 doses
were also associated with a trend toward a lower mor-
tality rate compared to placebo (p = 0.04 for 100 mg
and p = 0.06 for 150 mg). No significant differences in
terms of mortality rates with the treatment groups com-
pared to placebo were reported.
Overall, there were comparable incidences of adverse
events among all groups with comparable rates of severe/
life-threatening effects as well. The adverse events which
most commonly led to treatment discontinuation were
diarrhea, nausea, and vomiting and were reported in the
group receiving 150 mg twice a day [13].
The TOMORROW trial is planned to be followed
by an open-label continuation phase in which efficacy
and safety of BIBF-1120 are planned to be further
studied [15].
Two phase III studies aimed at evaluating the efficacy
and safety of BIBF 1120 150 mg×2/day over 52 weeks in
patients with IPF are also planned. These two studies
have similar endpoints which include the annual decline
rate in FVC, quality of life and time to first exacerbation,
overall survival [16].Conclusions
IPF is a debilitating disease associated with a limited
life span and characterized by an anarchic, rapidly
progressing fibrogenesis. The pathogenesis of the IPF
is complex and involves the interaction of multiple
mediator-driven pathways having as common (up)
regulator the TGF-β and including growth factors such
as PDGF, bFGF or VEGF. The preclinical and clinical
data demonstrated that the concomitant inhibition of
such factors with compounds such as BIBF 1120 is
able to slow the progression of lung fibrosis and to
improve the disease outcome. However further clinical
data are needed to better document the clinical effi-
cacy and safety of BIBF 1120 and to better position
this potential therapy in the IPF management.
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